Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9257 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan 1, 2010 In Use
J9035 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan 1, 2005 In Use
S0116 Bevacizumab Avastin 100 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jul 1, 2004 Jun 30, 2006 No Longer Used
NA Alectinib Alecensa 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2015 In Use
C9214 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Feb 26, 2004 Dec 31, 2004 No Longer Used
Q5129 Bevacizumab-adcd Vegzelma 10mg Immunotherapy Monoclonal Antibody VEGFR No 2023 Mar 17, 2023 In Use
Q5107 Bevacizumab-awwb Mvasi 10mg Immunotherapy Monoclonal Antibody VEGFR No 2018 Jan 1, 2019 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov 28, 2022 In Use
C9142 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Sep 27, 2022 Dec 21, 2022 No Longer Used
NA Bexarotene Targretin 75mg Chemotherapy Immunomodulator Retinoic Acid Derivative Yes 2014 In Use
NA Abiraterone acetate Zytiga 250 mg Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Yes 2011 In Use
NA Bicalutamide Casodex 50 mg Hormonal Therapy Androgen Receptor Inhibitor non-steriodal Yes 1995 In Use
NA Binimetinib Mektovi 15mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2018 In Use
C9417 Bleomycin Bleomycin 15 units Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1973 Jan 1, 2004 Dec 31, 2005 No Longer Used
J9040 Bleomycin Bleomycin 15 units Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1973 Jan 1, 1984 In Use
C9449 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Apr 1, 2015 In Use
J9039 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Jan 1, 2016 In Use
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2005 In Use
C9243 Bendamustine Treanda 1 mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2008 Oct 1, 2008 Dec 31, 2008 No Longer Used
J9044 Bortezomib Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2019 Nov 3, 2019 Dec 21, 2022 In Use
J9046 Bortezomib (Dr Reddy) Bortezomib (Dr Reddy) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9048 Bortezomib (Fresniuskab) Bortezomib (Fresniuskab) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2017 Dec 21, 2022 In Use
J9049 Bortezomib (Hospira) Bortezomib (Hospira) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9056 Bendamustine Vivimusta 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.